A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2019-02-25
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in
subjects with probable AD who have symptoms of agitation and aggression